Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMDW) Capital Expenditures (2019 - 2025)

Historic Capital Expenditures for Revolution Medicines (RVMDW) over the last 7 years, with Q3 2025 value amounting to $3.3 million.

  • Revolution Medicines' Capital Expenditures fell 485.8% to $3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.3 million, marking a year-over-year increase of 3406.12%. This contributed to the annual value of $10.3 million for FY2024, which is 3336.78% up from last year.
  • Revolution Medicines' Capital Expenditures amounted to $3.3 million in Q3 2025, which was down 485.8% from $7.4 million recorded in Q2 2025.
  • In the past 5 years, Revolution Medicines' Capital Expenditures ranged from a high of $7.4 million in Q2 2025 and a low of $454000.0 during Q3 2021
  • In the last 5 years, Revolution Medicines' Capital Expenditures had a median value of $2.5 million in 2022 and averaged $2.6 million.
  • As far as peak fluctuations go, Revolution Medicines' Capital Expenditures surged by 67643.17% in 2022, and later tumbled by 5570.07% in 2023.
  • Revolution Medicines' Capital Expenditures (Quarter) stood at $1.2 million in 2021, then surged by 143.11% to $2.9 million in 2022, then fell by 19.44% to $2.3 million in 2023, then crashed by 47.26% to $1.2 million in 2024, then skyrocketed by 174.06% to $3.3 million in 2025.
  • Its last three reported values are $3.3 million in Q3 2025, $7.4 million for Q2 2025, and $3.3 million during Q1 2025.